vendredi 1 mars 2019

Onco Actu du 1er mars 2019

1. BIOLOGIE

Atlas of acute myeloid leukemia cell types may lead to improved, targeted therapies [Mass. General Hospital]

1.4 BIOLOGIE - TECHNOS

Gene-editing causes accidental changes — scientists now have a new way to track them [Stanford]

The Challenge of Using CRISPR to Knock In Genes [The Scientist]

CRISPR offshoot still makes mistakes editing DNA, raising concerns about its medical use [Science]

2.6 ETIOLOGIE - ENVIRONNEMENT

Radioactive cancer drugs could pose risk to cremation workers [Reuters]

4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...

First guidance on new rules for certain medical devices [EMA]

4.12 BIOPSIES LIQUIDES

Geisinger, Johns Hopkins Testing Liquid Biopsy Assay for Early Cancer Detection [Genome Web]

4.2 DÉP., DIAG. & PRONO. - GÉNOME

Medicare should stop blocking access to next-generation sequencing for people with hereditary cancer [STAT]

Health minister: NHS must lead the world in genomic healthcare [GOV.UK]

How to lead the world (in genomic healthcare) [PHG Foundation]

4.9 DÉP., DIAG. & PRONO. - SEIN

How a new breast cancer biomarker could help patients identify best treatment options [The Conversation]

5.1 TRAITEMENTS - PRÉ-CLINIQUE

How prostate cancer becomes treatment resistant [Sanford Burnham Prebys Medical Discovery Institute]

5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS

Bispecifics player Abpro teams up with China’s NJCTTQ in biobucks deal worth up to $4B [Fierce Biotech]

5.2.1 PHARMA - PARTENARIATS

J&J bags option on AdoRx lung cancer drugs [Fierce Biotech]

5.2.2 PHARMA - FUSIONS & ACQUISITIONS

Celgene Complications [In The Pipeline]

5.3 TRAITEMENTS - FDA, EMA, NICE...

FDA cautions patients, providers about using robotically-assisted surgical devices for mastectomy and other cancer-related surgeries [FDA]

FDA sounds an alarm on using robotic devices in cancer surgeries, citing concerns about safety and results [STAT]

Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program [JAMA Oncology]

5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers [Roche]

5.4 TRAITEMENTS - ECONOMIE

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [NICE]

5.9 AACR

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019 [Amgen]

6. LUTTE CONTRE LES CANCERS

Cancer Trends Progress Report [NCI]

NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration [NCI]

6.10 POLITIQUES

Paul Nurse on Brexit: ‘UK is sleepwalking into a disaster’ [Nature]

6.6 PUBLICATIONS

University of California boycotts publishing giant Elsevier over journal costs and open access [Science]

Big pharma is embracing open-access publishing like never before [Nature]

Huge US institution cancels subscription with Elsevier [Nature]

University of California breaks up with major publisher over research access dispute [STAT]

6.7.1 IA/BIOINFORMATIQUE

AI will not solve health care challenges now, but there are innovative alternatives, researcher writes [Stanford]

6.9 CONTROVERSES

Update on NIH’s efforts to address sexual harassment in science [NIH]

National Institutes of Health apologizes for lack of action on sexual harassers [Science]